Pfizer Coronavirus Vaccine Reported to be 90 Percent Effective in Phase III Trial

Pfizer coronavirus vaccine
Image by Gerd Altmann from Pixabay

Currently, there are a number of trials for the development of coronavirus infection vaccination going around the world. The Pfizer And BioNTech clinical trial has so far reported success more than any other trial. Now, more good news has been reported by pharmaceutical companies.

In accordance with the latest reports from the largest and final Phase III of the trial, the Pfizer coronavirus vaccine is more than ninety percent effective. Additionally, no adverse outcomes that are associated with its use have been noted so far.

The final phase of the clinical trial started back at the end of the month of July. At the moment, over forty thousand people are participating in the trial.

A total of thirty-eight thousand, nine hundred and fifty-five people have also been administered a second dosage of the vaccination formula out of the total number of participants.

These participants have been recruited from not only the US but from other countries including Turkey, Germany, Argentina, South Africa, and Brazil.

After receiving the first dose of the vaccine, it was noted that immunity and protection were achieved by the participants within a time period of twenty-eight days. When given a second dose, the results came much faster in only seven days.

Hence, the Pfizer coronavirus vaccine was found to be effective in protection from the SARS-CoV-2, or the virus responsible for causing coronavirus infection by ninety percent in people who had not contracted the virus.

RELATED: Antibiotic Resistance is a Bigger Threat to Public Health than Coronavirus 

Secondly, there were no serious side effects in nearly all of the participants receiving the dose, which came as a surprise as existent research on developing vaccinations for similar infections including pneumonia or flu suggests that negative outcomes are typically seen in all phases during clinical trials.

The chairman and CEO of Pfizer, Dr. Albert Bourla, commented on the success of the trials, saying that the results show further add to the early evidence for the effectiveness of the vaccine formula by the companies.

Furthermore, Dr. Albert also added that the positive results take the world closer to gaining global immunity and control over the pandemic.

Both BioNTech and Pfizer have also officially given a statement regarding mass production of the vaccine, saying that fifty million doses would be produced by the end of December. In the following year. they also plan to develop 1.3 billion more doses for global distribution.

Even though the ongoing trial has reported success, it should still be kept in mind that more time is needed to evaluate the effects of the Pfizer coronavirus vaccine. At the moment, the results are only interim.

According to the U.S. Food and Drug Administration’s Emergency Use Authorization. (EUA), a time span of two months is required to investigate the potential effects of a vaccine formula after being administered for the final time.

Therefore, in the coming two months, the clinical trial will continue to test the efficacy of the vaccine as well as a lookout for any adverse impact. During this time period, the results may even change.

After two months, the data of the trial will be peer-reviewed and put up for approval by health agencies globally. In case the Pfizer vaccine gets approval, it will be the first coronavirus vaccine that completed all three phases of a clinical trial.


Please enter your comment!
Please enter your name here